Cargando…
Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease
PURPOSE: This study evaluated the predictive role of fecal calprotectin (FC) measured at an early stage of treatment for monitoring clinical remission (CR) after six months and endoscopic remission (ER) after one year of treatment in pediatric Crohn’s disease (CD). METHODS: This retrospective study...
Autores principales: | Lee, Yeoun Joo, Park, Jae Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482829/ https://www.ncbi.nlm.nih.gov/pubmed/36148291 http://dx.doi.org/10.5223/pghn.2022.25.5.396 |
Ejemplares similares
-
Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial
por: Aniwan, Satimai
Publicado: (2022) -
Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022) -
Can fecal calprotectin better stratify Crohn’s disease activity index?
por: Scaioli, Eleonora, et al.
Publicado: (2015) -
Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis
por: Chen, Fang, et al.
Publicado: (2021) -
Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)